Nonetheless, ERBB signal inhibitors have demonstrated promising efficacy in clinical trials across multiple tumor types, including GC and esophageal cancer.[38,39] Further research and clinical investigation are warranted to elucidate their exact role and therapeutic efficacy in the management of this specific subtype of cancer. Here, EGFR is linked to neoplasm.